What is the current Price Target for the HBM Healthcare Investments stock?

The average HBM Healthcare Investments target price is CHF233.50. This is 34.97% higher than the current stock price. The highest price target is 36.42%, the lowest is 33.53%. 2 Analysts have issued a price target HBM Healthcare Investments 2026 .

How high will the HBM Healthcare Investments stock rise?

No reliable answer can be given as to how high the HBM Healthcare Investments stock will rise. The performance of stocks, including the HBM Healthcare Investments stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the HBM Healthcare Investments stock today?

The performance of HBM Healthcare Investments stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the HBM Healthcare Investments stock fall?

The decline in HBM Healthcare Investments stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

HBM Healthcare Investments Forecast, price target & analysts

CHF173.00

4.74% today

SIX Swiss Exchange, Apr 04, 05:30 pm CET

ISIN

CH0012627250

Symbol

HBMN

Sector

Finances

Industry

Asset manager

Overview Dividends Analysts Charts News Strategies

HBM Healthcare Investments Target price 2025 - Analyst rating & recommendation

HBM Healthcare Investments Classifications & Recommendation:

Buy

100%

HBM Healthcare Investments Price Target

Target Price	CHF233.50
Price	CHF173.00
Potential	34.97% register free of charge
Number of Estimates	2

	2 Analysts have issued a price target HBM Healthcare Investments 2026 . The average HBM Healthcare Investments target price is CHF233.50. This is 34.97% register free of charge higher than the current stock price. The highest price target is CHF236.00 36.42% register free of charge , the lowest is CHF231.00 33.53% register free of charge .
	A rating was issued by 2 analysts: 2 Analysts recommend HBM Healthcare Investments to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the HBM Healthcare Investments stock has an average upside potential 2026 of 34.97% register free of charge . Most analysts recommend the HBM Healthcare Investments stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Mar '24	2025 Estimates
Earnings Per Share CHF	-0.16	7.24
	99.24%	4,625.00%
P/E		25.08
EV/Sales		18.10

1 Analysts have issued a HBM Healthcare Investments forecast for earnings per share. The average HBM Healthcare Investments EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	CHF-0.16	99.24%
2025	CHF7.24 4,625.00% Unlock
2026	CHF15.29 111.19% Unlock
2027	CHF15.60 2.03% Unlock

Current	61.87	786.68%
2025	25.08 59.46% Unlock
2026	11.88 52.63% Unlock
2027	11.64 2.02% Unlock

HBM Healthcare Investments...

Current HBM Healthcare Investments Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
BAADER HELVEA EQUITY RESEARCH	Locked ➜ Locked	Locked	Oct 20 2024

Analyst Rating	Date
Locked BAADER HELVEA EQUITY RESEARCH: Locked ➜ Locked	Oct 20 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now